<?xml version='1.0' encoding='utf-8'?>
<document id="11642691"><sentence text="Fluoroquinolone adverse effects and drug interactions."><entity charOffset="0-15" id="DDI-PubMed.11642691.s1.e0" text="Fluoroquinolone" /></sentence><sentence text="Extensive pharmacologic and clinical development of quinolone antimicrobial agents has resulted in improved antimicrobial activity, pharmacokinetic features, toxicity, and drug-drug interaction profiles"><entity charOffset="52-61" id="DDI-PubMed.11642691.s2.e0" text="quinolone" /></sentence><sentence text=" Nalidixic acid and other early quinolones had limited use due to poor pharmacokinetics, relatively narrow antimicrobial spectrum of activity, and frequent adverse effects"><entity charOffset="1-15" id="DDI-PubMed.11642691.s3.e0" text="Nalidixic acid" /><entity charOffset="32-42" id="DDI-PubMed.11642691.s3.e1" text="quinolones" /><pair ddi="false" e1="DDI-PubMed.11642691.s3.e0" e2="DDI-PubMed.11642691.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11642691.s3.e0" e2="DDI-PubMed.11642691.s3.e1" /></sentence><sentence text=" Beginning with the development of fluoroquinolones, such as norfloxacin and ciprofloxacin, in the 1980s, the agents assumed a greatly expanded clinical role because of their broad antimicrobial spectrum of action, improved pharmacokinetic properties, and more acceptable safety profile"><entity charOffset="35-51" id="DDI-PubMed.11642691.s4.e0" text="fluoroquinolones" /><entity charOffset="61-72" id="DDI-PubMed.11642691.s4.e1" text="norfloxacin" /><entity charOffset="77-90" id="DDI-PubMed.11642691.s4.e2" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.11642691.s4.e0" e2="DDI-PubMed.11642691.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11642691.s4.e0" e2="DDI-PubMed.11642691.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11642691.s4.e0" e2="DDI-PubMed.11642691.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11642691.s4.e1" e2="DDI-PubMed.11642691.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11642691.s4.e1" e2="DDI-PubMed.11642691.s4.e2" /></sentence><sentence text=" Although the pharmacokinetics and efficacy of the drugs have improved significantly, a major area of continued emphasis is to further reduce the frequency and severity of adverse events and drug-drug interactions" /><sentence text=" Older agents such as ciprofloxacin and ofloxacin are still extensively prescribed, but the focus of this article is on the newer fluoroquinolones (levofloxacin and other drugs that have been approved or have been under investigation since approximately 1997)"><entity charOffset="22-35" id="DDI-PubMed.11642691.s6.e0" text="ciprofloxacin" /><entity charOffset="40-49" id="DDI-PubMed.11642691.s6.e1" text="ofloxacin" /><entity charOffset="148-160" id="DDI-PubMed.11642691.s6.e2" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.11642691.s6.e0" e2="DDI-PubMed.11642691.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11642691.s6.e0" e2="DDI-PubMed.11642691.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11642691.s6.e0" e2="DDI-PubMed.11642691.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11642691.s6.e1" e2="DDI-PubMed.11642691.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11642691.s6.e1" e2="DDI-PubMed.11642691.s6.e2" /></sentence><sentence text="" /></document>